[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Varian, a Siemens Healthineers Company\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":175},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,72,99,121,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100501058","daily-adaptive-radiation-therapy-using-an-individualized-approach-for-prostate-cancer-100501058",false,"NCT05804318","Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer","Daily Adaptive Stereotactic Body Radiation Therapy for Prostate Cancer With Urethral Sparing: A Prospective Trial Using an Individualized Approach to Reduce Urinary Toxicity","ARTIA-Prostate","Inclusion Criteria:\n\n1. Patient has NCCN low or intermediate risk prostate cancer that is biopsy proven.\n2. Prostate volume is ≤80cc as assessed by MRI prior to radiotherapy.\n3. AUA\u002FIPSS score is ≤ 15.\n4. ECOG performance status is ≤2 (or Karnofsky score is ≥60%).\n5. Patient has no PIRADS 4 or 5 lesion on prostate MRI contacting the urethra (determined at physician discretion).\n6. Patient has the ability to complete required patient questionnaires.\n7. Patient age ≥ 18 years (or greater than the local age of majority).\n8. Patient has the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patient has baseline grade ≥3 GI or GU toxicity\n2. Patient has had prior overlapping pelvic radiotherapy.\n3. Patient has had prior transurethral resection of the prostate, prostate HIFU, or cryoablation.\n4. Patient has node positive prostate cancer.\n5. Patient has extracapsular extension (capsular abutment is permitted).\n6. Patient has active inflammatory bowel disease or active collagen vascular disease.\n7. Patient cannot undergo prostate MRI.\n8. Patient cannot undergo prostate fiducial marker placement.\n9. Patient has ongoing receipt of cytotoxic chemotherapy (androgen deprivation therapy is allowed).","MALE","18 Years",{"count":20,"type":21},132,"ESTIMATED","INTERVENTIONAL",[24],"NA","This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.",[27],"Prostate Cancer","RECRUITING","2026-05-27",{"date":31,"type":32},"2026-05-28","ACTUAL",{"date":34,"type":32},"2023-04-13",{"date":36,"type":21},"2031-07",{"name":38,"class":39},"Varian, a Siemens Healthineers Company","INDUSTRY",8,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100498047","cardiac-radioablation-versus-repeat-catheter-ablation-a-pivotal-randomized-clinical-trial-evaluating-safety-and-efficacy-for-patients-with-high-risk-refractory-ventricular-tachycardia-radiate-vt-100498047","NCT05765175","Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)","Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia","RADIATE-VT","Inclusion Criteria:\n\n1. High-risk refractory VT, defined as:\n\n   1. Ischemic and\u002For nonischemic cardiomyopathy, and\n   2. Recurrent sustained monomorphic VT, defined as at least one of the following below, documented by ICD interrogation or ECG in the prior 6 months, and having occurred after the last VT ablation:\n\n      A: ≥3 episodes of monomorphic VT treated with anti-tachycardia pacing (ATP) at least one of which is symptomatic\n\n      B: ≥1 appropriate ICD shock\n\n      C: ≥3 episodes of sustained monomorphic VT within 24 hours treated with ICD shock or ATP\n\n      D: sustained monomorphic VT below detection rate of ICD documented by ECG, and\n   3. Left ventricular ejection fraction (LVEF) ≤49% and\n   4. Previously underwent at least one standard of care CA for VT.\n2. Presence of a clinical indication for a repeat CA procedure for scar-mediated VT in the judgement of the treating investigator.\n3. Has failed amiodarone therapy or is intolerant to amiodarone:\n\n   * Failed amiodarone therapy is defined as: appropriate ICD therapy or sustained monomorphic VT having occurred while the patient was taking amiodarone (minimum cumulative dose of 10 g).\n   * Intolerant to amiodarone is defined as: previously tried or taken amiodarone but stopped due to medication related side effects or toxicities.\n4. Deemed to be medically and technically a candidate for further CA by the electrophysiologist investigator.\n5. Presence of an ICD.\n6. At least 18 years of age (or meets local age of majority).\n7. Ability to understand and willingness to sign an IRB approved written informed consent document.\n\nExclusion Criteria:\n\n1. Contraindication to a CA procedure for VT (e.g., presence of mobile LV thrombus, active systemic infection, active ischemic or other reversible causes of VT).\n2. Patients with expected, right ventricular scar only.\n3. Any prior radiation to the thorax region of the body.\n4. Known medical conditions associated with higher risk of radiotherapy complications in the judgement of the radiation oncologist (i.e., active connective tissue disorders, interstitial lung disease, etc.) that would preclude safe delivery of CRA.\n5. Current use of inotropes.\n6. Presence of a left-ventricular assist device (LVAD).\n7. Scheduled for LVAD or heart transplant procedures.\n8. Presence of a systemic illness likely to limit survival to \\\u003C 1 year.\n9. VT ablation procedure performed within the prior 2 weeks.\n10. Polymorphic VT or ventricular fibrillation (VF) as the primary clinical heart rhythm, as indicated by 12-lead ECG and\u002For ICD interrogation.\n11. \\>3 distinct clinical monomorphic VT morphologies on ICD interrogation since the prior CA, or \\>5 induced monomorphic VT morphologies during NIPS testing.\n12. Incessant VT that is hemodynamically unstable.\n13. Bundle branch reentry (BBR) VT.\n14. Pregnant and\u002For breastfeeding. (Patient denial is sufficient for enrollment).\n15. Patients of childbearing potential who:\n\n    * are not on a medically effective means of birth control at the time of screening or do not start a medically effective means of birth control prior to randomization; or\n    * do not agree to continue medically effective means of birth control until they have completed their assigned therapy; or\n    * do not agree to be on a medically effective means of birth control if they are treated with CRA after their index CA procedure.\n16. Patients enrolled in another clinical study the investigator believes to be in conflict with this clinical investigation.\n17. Patients enrolled or planned to be enrolled in another cardiac radioablation clinical study or registry.\n18. Patients with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation.","ALL",{"count":51,"type":21},380,[24],"RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA.",[55],"Tachycardia, Ventricular",[57,58,59,60,61,62],"Cardiac radioablation","Ventricular tachycardia","Catheter ablation","Refractory ventricular tachycardia","High risk","SBRT","2026-04-17",{"date":65,"type":32},"2026-04-22",{"date":67,"type":32},"2023-04-21",{"date":69,"type":21},"2030-05",{"name":38,"class":39},11,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100568438","feasibility-study-of-cbct-for-igrt-in-cancer-patients-100568438","NCT06681233","Feasibility Study of CBCT for IGRT in Cancer Patients","A Feasibility Study of a Novel Cone-Beam CT Approach for Image Guided Radiotherapy in Cancer Patients","Inclusion Criteria:\n\n1. Patient age ≥ 18\n2. Patient is receiving radiation therapy for head and neck, thorax, liver, breast, genitourinary, or gastrointestinal malignancies\n3. A CBCT acquisition for localization is standard of care for the radiation therapy treatment plan being delivered\n\nExclusion Criteria:\n\n1. Patient has ECOG Performance Status ≥3.\n2. Patient is wheelchair bound.\n3. Patient has a life expectancy \\\u003C3 months.\n4. Patient is unwilling or unable to provide informed consent to participate in the study.\n5. Patient is pregnant or has plans for pregnancy during the period of treatment.\n6. Patient is part of a vulnerable population (per ISO 14155:2020, \"individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response\"). This includes prisoners.",{"count":80,"type":21},50,[24],"Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy but CBCT images have poor contrast and are susceptible to imaging artefacts that limit their usability for other tasks in the radiation therapy workflow.\n\nVarian Medical Systems, the sponsor of this study, has developed new CBCT imaging technology called HyperSight that so far has demonstrated increased image quality compared with conventional CBCT images. This new HyperSight CBCT imager has previously been built into Varian Halcyon and Ethos treatment machines, where the imager is enclosed in a ring that rotates around the patient. Now, HyperSight has been built into a Varian treatment machine, called TrueBeam, where the imager is mounted on a C-shaped arm that rotates around you to acquire an image.\n\nThis study is being done to evaluate the image quality of HyperSight CBCT compared to conventional CBCT images, and to determine whether HyperSight CBCT can improve the process of delivering radiation treatments.\n\nThe goal of this study is to collect images from this new HyperSight-TrueBeam CBCT imager from a variety of patients and locations in the body. The images will be analyzed to determine whether their quality is high enough to use for tasks other than positioning patients for treatment. For example, the study will determine whether the HyperSight images could be used to calculate a radiation plan.",[84,85,86,87,88,89],"Head and Neck Cancers","Breast Cancer","Thoracic Cancers","Liver Cancer","Genito Urinary Cancer","Gastrointestinal Cancers","2026-03-12",{"date":92,"type":32},"2026-03-13",{"date":94,"type":32},"2025-02-19",{"date":96,"type":21},"2026-09",{"name":38,"class":39},4,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":49,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100498012","stereotactic-adaptive-radiation-therapy-of-borderline-resectable-pancreatic-cancer-an-individualized-approach-100498012","NCT05764720","Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach","A Prospective Trial of Stereotactic Adaptive Radiation Therapy for Borderline Resectable\u002FLocally Advanced Pancreatic Cancer: An Individualized Approach to Minimizing Gastrointestinal Toxicity (ARTIA-Pancreas)","ARTIA-Pancreas","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed borderline-resectable (based on NCCN criteria), locally-advanced (based on NCCN criteria), or medically inoperable pancreatic adenocarcinoma.\n2. ECOG performance status 0-1\n3. Receipt of at least two months of lead-in chemotherapy (regimen at the discretion of the treating physician) prior to planned initiation of CT-STAR.\n4. Limited regional lymphadenopathy permitted. Node positive patients are restricted to those with up to 3 clinically involved (greater than 1cm on cross-sectional imaging or pathologically proven) nodes provided that the lymph nodes are adjacent to the primary tumor.\n5. At least 18 years of age.\n6. Must be able to take an interruption in systemic therapy at least one week prior to planned start of CT-STAR (two weeks preferred) lasting for the duration of CT-STAR and continuing for at least one week following end of CT-STAR (two weeks preferred).\n7. Capable of a single end-exhale breath-hold of at least 20 seconds in duration and of repeated end-exhale or deep inspiratory breath-hold of at least 10 seconds in duration upon verbal instruction.\n8. Anatomy of target and adjacent OARs adequately visualized on ETHOS simulation imaging, as determined by treating and study physicians.\n\n   Note: central review of simulation imaging and initial plan target\u002FOAR contours by the Principal Investigator and Physics lead is required for the first two patients at each participating institution prior to study treatment delivery. Patients with inadequate anatomic visualization at simulation will be considered screen-failures and treated off-protocol as per institutional standard-of-care.\n9. Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n\nExclusion Criteria:\n\n1. Past history of radiotherapy within the projected treatment field\n2. Prior, intercurrent, or planned receipt (within 90 days prior to or following SBRT) of any investigational agents related to pancreatic cancer diagnosis.\n3. Competing, active cancer diagnosis within the preceding one year.\n4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n5. Gross tumor invasion of the stomach or duodenum (defined either radiographically or endoscopically).\n6. Pregnant and\u002For breastfeeding. Patients of childbearing potential must have a negative pregnancy test within 14 days of study entry.",{"count":108,"type":21},134,[24],"This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced , or medically inoperable pancreatic adenocarcinoma will translate into a decreased toxicity. The study will evaluate GI toxicity, overall survival, local control, quality of life, and workflow metrics.",[112],"Pancreatic Cancer",{"date":114,"type":32},"2026-03-16",{"date":116,"type":32},"2023-05-14",{"date":118,"type":21},"2030-03-15",{"name":38,"class":39},3,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":129,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},"100454464","daily-adaptive-radiation-therapy-an-individualized-approach-for-carcinoma-of-the-cervix-100454464","NCT05197881","Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix","Daily Adaptive External Beam Radiation Therapy in the Treatment of Carcinoma of the Cervix: A Prospective Trial of an Individualized Approach for Intestinal Toxicity Reduction (ARTIA-Cervix)","ARTIA-Cervix","Inclusion Criteria:\n\n1. Patients must have histologically confirmed, newly diagnosed advanced cervical cancer (squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma): FIGO 2018 clinical stages IB2-IVA, without involved paraaortic lymph nodes.\n2. For patients with involved pelvic lymph nodes, the upper border of the CTV nodal volume may not extend above the confluence of the common iliac arteries with the aorta (i.e., aortic bifurcation).\n3. Patients must NOT have had a hysterectomy.\n4. Pelvic nodal status is to be confirmed by one or more of the following studies\u002Fprocedures: PET\u002FCT scan, CT scan, MR Scan, fine needle biopsy, extra peritoneal biopsy or laparoscopic biopsy, per institutional standard of care.\n5. Patients must be planning to undergo concurrent pelvic radiation and chemotherapy.\n6. ECOG performance status ≤ 2 (Karnofsky ≥60%).\n7. Patient must be willing and able to complete the PRO-CTCAE, EQ-5D, EPIC and EORTC questionnaires as described in the study protocol.\n8. Patient must have normal organ and marrow function as defined below:\n\n   * leukocytes ≥ 2,500\u002FmcL\n   * absolute neutrophil count ≥ 1,500\u002FmcL\n   * platelets ≥ 100,000\u002FmcL\n   * hemoglobin ≥ 8 g\u002FdL (can be transfused with red blood cells pre-study)\n   * total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN)\n   * AST(SGOT)\u002FALT(SGPT) ≤ 3 × ULN\n   * alkaline phosphatase ≤ 2.5 × ULN\n   * creatinine \\\u003C 1.5 mg\u002FdL to receive weekly cisplatin\\*\n\n     * Patients whose serum creatinine is between 1.5 and 1.9 mg\u002FdL are eligible for cisplatin if there is no hydronephrosis and the estimated creatinine clearance (CCr) is \\>30 ml\u002Fmin. For the purpose of estimating the CCr, the formula of Cockcroft and Gault for females should be used:CCr=(0.85 ×(140-age)×IBW)\u002F((Scr×72)) where age is the patient's age in years (from 20 to 80 years), Scr is the serum creatinine in mg\u002FdL, and IBW is the ideal body weight in kg (according to the calculation IBW = 45.5 kg + 2.3 kg for each inch over 5 feet).\n9. Age ≥ 18 years (or meets local age of consent).\n10. Study participant is already intending to be prescribed a standard of care cisplatin treatment regimen.\n11. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Prior radiation therapy to the pelvis or abdominal cavity, para-aortic lymph glands (PALN) radiation, or previous therapy of any kind for this malignancy.\n2. Patients with PALN nodal metastasis.\n3. Patients who have undergone staging pelvic and\u002For paraaortic lymphadenectomy.\n4. Prior allogeneic bone marrow transplantation or prior solid organ transplantation.\n5. Prior systemic anticancer therapy due to a diagnosis of cancer (e.g., chemotherapy, targeted therapy, immunotherapy) within 3 years prior to entering the study.\n6. Patients diagnosed on imaging or biopsy with a synchronous primary malignancy (with the exception of DCIS of the breast, or early stage basal cell carcinoma of the skin).\n7. Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease.\n8. Patients with a history of other symptomatic autoimmune disease: rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis (e.g., Wegener's Granulomatosis); CNS or motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome and Myasthenia Gravis, multiple sclerosis.).\n9. Patients with active tuberculosis (TB).\n10. Patients who are pregnant.\n11. Patients who are actively breastfeeding (or who do not agree to discontinue breastfeeding before the initiation of protocol therapy).\n12. Patients who are of child-bearing potential who do not agree to use birth control (for a minimum of 14 months after the last dose of cisplatin) in accordance with institution's standard of care.\n13. Patients with a prior known history or current diagnosis of a vesicovaginal, enterovaginal, or colovaginal fistula.\n14. Patients who undergo a pelvic or para-aortic lymph node dissection prior to planned chemoradiation therapy.\n15. Patients with known active infection of HIV.\n16. Patients with hip prosthetics","FEMALE",{"count":131,"type":21},125,[24],"This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).",[135],"Cervical Cancer by FIGO Stage 2018","2025-09-19",{"date":138,"type":32},"2025-09-23",{"date":140,"type":32},"2022-05-03",{"date":142,"type":21},"2030-09",{"name":38,"class":39},5,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":49,"minAge":153,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":160,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},"100471800","genicular-artery-embolisation-for-knee-osteoarthritis-ii-100471800","NCT05423587","Genicular Artery Embolisation for Knee Osteoarthritis II","Genicular artEry embolisatioN in patiEnts With oSteoarthrItiS of the Knee II","GENESISII","Inclusion Criteria:\n\nALL inclusion criteria below need to be fulfilled for the patient to participate in the study.\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Participants aged 45 years or above.\n* Grade 1-3 knee OA on X-ray as per Kellgren-Lawrence Grading Scale\n* Knee pain for at least 3 months resistant to conservative non-surgical treatment (e.g., physiotherapy, steroid injections, weight loss programs, PRP (platelet-rich plasma) injections)\n* Be able to lie flat for at least 6 hours-this will be assessed by asking how participants sleep (bed, chair recumbent, semi-recumbent) and assessing what prevents them from lying flat overnight (breathlessness, back pain, etc)\n* Minimum score of 50 on baseline 0 - 100 VAS\n\nExclusion Criteria:\n\nThe patient may not enter the study if ANY of the following apply:\n\n* Rheumatoid arthritis or infectious arthritis\n* Severe knee OA (grade 4 on x-ray as per Kellgren-Lawrence Grade)\n* Renal impairment: eGFR \\\u003C45. Assessed from medical records or a blood test if required as is part of standard clinical practice when considering a patient for a therapeutic intervention.\n* Patients with a bleeding diathesis, or other bleeding risk such as patients on warfarin which cannot be stopped easily (e.g., patients with metallic heart valves) assessed by asking the patient and from medical records. Uncorrectable bleeding diathesis: INR\\>1.6, Platelets \\\u003C50,000\n* Requires oxygen on ambulation. Assessed by asking the patient and from medical records.\n* Low life expectancy (\\\u003C1 year)\n* Communication difficulty due to language barriers\n* Contraindication to MRI\n* Known allergies to barium sulfate, 3-aminopropyltrialkoxysilane, polyphosphazene or IV radiopaque contrast agent\n* History of Peripheral Arterial Disease (PAD) with intermittent claudication and\u002For rest pain\n* Pregnancy or positive pregnancy test (the participant will be exposed to ionising radiation during the fluoroscopy procedure)\n* Any other significant disease or disorder which, in the opinion of the recruiting physician, may put the participants at risk because of participation in the study, or may influence the result of the study or the participant's ability to participate","45 Years",{"count":155,"type":21},110,[24],"This clinical study is designed as a double-blind sham controlled randomised trial with the option of sham group crossover to receive the GAE treatment at 6 months after unblinding. This study will determine if embolisation of abnormal neovasculature arising from branches of the genicular arteries reduces pain in patients with knee osteoarthritis. The study patient population will consist of up to 110 subjects with knee pain for at least 3 months that is resistant to conservative treatment measures. Subjects will be treated with knee embolisation or 2 mL of saline in the sham arm. At 6 months, all subjects in the sham arm will be allowed to cross-over and receive the embolisation procedure with a follow-up duration of 18 months. The total planned study duration is 3.5 years.",[159],"Knee Osteoarthritis",[161,162,163,164,165],"Microspheres","Embozene","Artery Embolization","Joint diseases","Osteoarthritis, Knee","2024-11-28",{"date":168,"type":32},"2024-12-03",{"date":170,"type":32},"2022-10-30",{"date":172,"type":21},"2028-06-30",{"name":38,"class":39},1,""]